A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810

Seven-transmembrane receptors

Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,712

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326

Raf-1 activates MAP kinase-kinase

Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263

Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein

Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrı́msson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,092

Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization

Bolan, P. O., Zviran, A., Brenan, L., Schiffman, J. S., Dusaj, N. N., Goodale, A. B., Piccioni, F., Johannessen, C. M., & Landau, D. A. (2019) · Cell Systems · doi:10.1016/j.cels.2019.10.002 · Cited by 15

HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells

Ha, S.-D., Lewin, N., Li, S. S. ‐., & Kim, S. O. (2021) · Cells · doi:10.3390/cells10051101 · Cited by 15

Ethanol Metabolism and Melanoma

Zhai, Z., Yamauchi, T., Shangraw, S., Hou, V., Matsumoto, A., & Fujita, M. (2023) · Cancers · doi:10.3390/cancers15041258 · Cited by 15

Novel Treatments in Development for Melanoma

Bernatchez, C., Cooper, Z. A., Wargo, J. A., Hwu, P., & Lizee, G. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_16 · Cited by 15

1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M

Kundu, A., Khouri, M. G., Aryana, S., & Firestone, G. L. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx103 · Cited by 15

Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells

Ahmed, R. A., Muralidharan, R., Srivastava, A., Johnston, S. E., Zhao, Y. D., Ekmekçioglu, S., Munshi, A., & Ramesh, R. (2021) · Cancers · doi:10.3390/cancers13020166 · Cited by 15

The epigenome and the many facets of cancer drug tolerance

Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14

The chilling of adenylyl cyclase 9 and its translational potential

Antoni, F. A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109589 · Cited by 14

Generation and analysis of zebrafish melanoma models

Wojciechowska, S., van Rooijen, E., Ceol, C. J., Patton, E. E., & White, R. M. (2016) · Methods in cell biology · doi:10.1016/bs.mcb.2016.03.008 · Cited by 13

Identification of Upstream Kinases by Fluorescence Complementation Mass Spectrometry

Zeng, L., Wang, W., Arrington, J. V., Shao, G., Geahlen, R. L., Hu, C., & Tao, W. A. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00261 · Cited by 13

Optogenetics in cancer drug discovery

Kiełbus, M., Czapiński, J., Odrzywolski, A., Stasiak, G., Szymanska, K., Kałafut, J., Kos, M., Giannopoulos, K., Stepulak, A., & Rivero‐Müller, A. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437138 · Cited by 13

A novel anti-melanoma SRC-family kinase inhibitor

Halaban, R., Bacchiocchi, A., Straub, R., Cao, J. P., Sznol, M., Narayan, D., Allam, A., Krauthammer, M. O., & Mansour, T. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26787 · Cited by 13

Functionalization of Nanomaterials for Skin Cancer Theranostics

Zhang, C., Zhu, X., Hou, S., Pan, W., & Liao, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.887548 · Cited by 13

Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy

Carelock, M. E., Master, R. P., Kim, M., Jin, Z., Wang, L. A., Maharjan, C. K., Hua, N., De, U., Kolb, R. H., Xiao, Y., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad019 · Cited by 13

Reading between the lines; understanding drug response in the post genomic era

Alifrangis, C., & McDermott, U. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.014 · Cited by 13

Inhibitory Effect of Sesamolin on Melanogenesis in B16F10 Cells Determined by In Vitro and Molecular Docking Analyses

Baek, S., Kang, M.-G., & Park, D. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666191011151123 · Cited by 13

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib

Zhou, X., Li, X., Liao, L., Han, J., Huang, J. L., Li, J., Tao, H., Fan, S., Chen, Z., Li, Q., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00643-2 · Cited by 13

Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform

Dorighi, K. M., Zhu, A., Fortin, J., Lo, J. H.-H., Sudhamsu, J., Wendorff, T. J., Durinck, S., Callow, M. G., Foster, S. A., & Haley, B. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114313 · Cited by 11

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations

Valčíková, B., Vadovičová, N., Smolkova, K., Zacpalova, M., Krejčı́, P., Lee, S., Rauch, J., Kölch, W., von Kriegsheim, A., Dorotikova, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321305121 · Cited by 12

Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas

Kessler, L. V., Malik, S., Leoni, M., & Burrows, F. J. (2021) · Cancers · doi:10.3390/cancers13215310 · Cited by 12

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma

Capaldo, B. J., Roller, D. G., Axelrod, M. J., Koeppel, A. F., Petricoin, E. F., Slingluff, C. L., Weber, M. J., Mackey, A. J., Gioeli, D. G., & Bekiranov, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138210 · Cited by 12

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

Smith, A. M., Zhang, C. R., Cristino, A. S., Grady, J. P., Fink, J. L., & Moore, A. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27206 · Cited by 12

Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma

Schäfer, A., Haenig, B., Erupathil, J., Strickner, P., Sabato, D., Welford, R. W. D., Klaeylé, L., Simon, E., Krepler, C., Brafford, P. A., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01628-x · Cited by 12

Atypic SUMOylation of Nor1/NR4A3 regulates neural cell viability and redox sensitivity

Gagnon, J., Caron, V., Gyenizse, L., & Tremblay, A. (2021) · The FASEB Journal · doi:10.1096/fj.202100395r · Cited by 12

MITF suppression by CH5552074 inhibits cell growth in melanoma cells

Aida, S., Sonobe, Y., Yuhki, M., Sakata, K., Fujii, T., Sakamoto, H., & Mizuno, T. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3317-6 · Cited by 12

Promoter methylation induced epigenetic silencing of DAZAP2, a downstream effector of p38/MAPK pathway, in multiple myeloma cells

Li, J., Hu, W., Luo, S., Xiong, D., Sun, S., Wang, Y., Bu, X., Liu, J., & Hu, J. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.04.012 · Cited by 11

OPN3 Regulates Melanogenesis in Human Congenital Melanocytic Nevus Cells through Functional Interaction with BRAFV600E

Dong, X., Zeng, W., Zhang, W., Lan, Y., Wang, Y., Feng, J., Gu, L., & Lü, H. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.04.022 · Cited by 11

miR-224–5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway

Liu, Y., Ruan, H., Lu, F., Peng, H., & Luan, W. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154772 · Cited by 11

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors

Lee, K. H., Goh, J., Kim, Y., & Kim, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-76909-2 · Cited by 10

The genetic and epigenetic basis of distinct melanoma types

Oba, J., & Woodman, S. E. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15957 · Cited by 10

PPP6C, a serine-threonine phosphatase, regulates melanocyte differentiation and contributes to melanoma tumorigenesis through modulation of MITF activity

Maskin, C. R., Raman, R., & Houvras, Y. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-08936-0 · Cited by 11

The universal role of adaptive transcription in health and disease

Lissek, T. (2024) · FEBS Journal · doi:10.1111/febs.17324 · Cited by 12

Le mélanome cutané

Gesbert, F., & Larue, L. (2018) · médecine/sciences · doi:10.1051/medsci/20183405013 · Cited by 10

TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors

de Oliveira, E. A., Chauhan, J. S., da Silva, J. R., Carvalho, L. A. D. C., Dias, D., de Carvalho, D. G., Watanabe, L. R. M., Rebecca, V. W., Mills, G. B., Lu, Y., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105911 · Cited by 11

RB1, Cancer Lineage Plasticity, and Therapeutic Resistance

Zhang, L., & Goodrich, D. W. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-092840 · Cited by 10

Towards individualized cancer therapy: Challenges and prospects

Hutchinson, E. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.008 · Cited by 10

Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection

Rosero, R. A., Villares, G. J., & Bar‐Eli, M. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00112 · Cited by 10

Elevated cyclic AMP levels promote BRAF/Pten mouse melanoma growth but pCREB is negatively correlated with human melanoma progression

Rodríguez, C. I., Castro‐Pérez, E., Longley, B. J., & Setaluri, V. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.027 · Cited by 11

Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma

Barreno, A., & Orgaz, J. L. (2022) · Cells · doi:10.3390/cells11030518 · Cited by 9

Linking SOX10 to a slow-growth resistance phenotype

Zhang, G., & Herlyn, M. (2014) · Cell Research · doi:10.1038/cr.2014.67 · Cited by 9

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas

Vachtenheim, J., & Ondrušová, Ľ. (2021) · Life · doi:10.3390/life11050424 · Cited by 10

Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer

Carper, M. B., Goel, S., Zhang, A. M., Damrauer, J. S., Cohen, S. M., Zimmerman, M. P., Gentile, G. M., Parag‐Sharma, K., Murphy, R. M., Sato, K., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100799 · Cited by 9

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection

Flynn, M., Pickering, L. M., Larkin, J., & Turajlic, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918777427 · Cited by 9

RhoA activation promotes glucose uptake to elevate proliferation in MAPK inhibitor resistant melanoma cellsPreprint

Murali, V. S., Rajendran, D., Isogai, T., DeBerardinis, R. J., & Danuser, G. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.09.574940 · Cited by 9

Multiple signaling pathways converge on proapoptotic protein BAD to promote survival of melanocytes

Sastry, K. S., Ibrahim, W. N., & Chouchane, A. I. (2020) · The FASEB Journal · doi:10.1096/fj.202001260rr · Cited by 8

Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy

Konstantakou, E. G., Velentzas, A. D., Anagnostopoulos, A. K., Giannopoulou, A. F., Anastasiadou, E., Papassideri, I. S., Voutsinas, G. E., Tsangaris, G. T., & Stravopodis, D. J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.11.015 · Cited by 8

Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival

Ferguson, J., Wilcock, D. J., McEntegart, S., Badrock, A. P., Levesque, M. P., Dummer, R., Wellbrock, C., & Smith, M. P. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12812 · Cited by 8

Targeting T-type channels in cancer: What is on and what is off?

Visa, A., Alza, L., Casas-Benito, A., Herreros, J., & Cantı́, C. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.021 · Cited by 7

Cheminformatics and Bioinformatics at the Interface with Systems Biology

Kaushik, A. C., Mehmood, A., Wei, D., Nawab, S., Sahi, S., & Kumar, A. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166037 · Cited by 7

Paradigm of biomarkers in metastatic melanoma (Review)

Pekarek, L., Cedra, A., Dbouk, Y., Ospino, L. R., Pedrejón, B. I., Bernier, L., Cervantes, E. D. R., Cendra, C. S., Cassinello, J., Trasobares, L., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14824 · Cited by 9

Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage

Wu, L.-Z., Huang, Y., Hu, H.-J., Hong, W., Yan, H., Ai, Y.-L., Mi, X.-Y., Feng, D.-Y., Guo, J.-Y., Ding, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02528-w · Cited by 6

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping

Kang, Y., Ji, Z., Li, H., & Tsao, H. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.03.039 · Cited by 6

Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing

Mukhtar, A., Morgan, H. J., Gibbs, A., Davies, G. E., Lovatt, C., & Patel, G. K. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljad502 · Cited by 6

A comprehensive review of targeting RAF kinase in cancer

Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177142 · Cited by 6

Progress towards precision functional genomics in cancer

Johannessen, C. M., & Boehm, J. S. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.02.002 · Cited by 6

Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes

Singleton, K. R., & Wood, K. C. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.112 · Cited by 6

Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor

Naffouje, S. A., Naffouje, R., Chen, J., & Salti, G. I. (2016) · Anticancer Research · doi:10.21873/anticanres.11266 · Cited by 7

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma

Banik, I., Ghosh, A., Beebe, E., Burja, B., Frank‐Bertoncelj, M., Dooley, C. M., Markkanen, E., Dummer, R., Busch‐Nentwich, E. M., & Levesque, M. P. (2023) · Cancers · doi:10.3390/cancers15030877 · Cited by 7

A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection

Bai, J. P. F., Sakellaropoulos, T., & Alexopoulos, L. G. (2017) · Toxins · doi:10.3390/toxins9030099 · Cited by 5

Development of an HTS-Compatible Assay for Discovery of Melanoma-Related Microphthalmia Transcription Factor Disruptors Using AlphaScreen Technology

Wang, J., Fang, P., Chase, P. S., Tshori, S., Razin, E., Spicer, T., Scampavia, L. D., Hodder, P., & Guo, M. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116675274 · Cited by 5

Molecular Determinants of Chemotherapy Resistance in Ovarian Cancer

Cooley, M., Fang, P., Fang, F., Nephew, K. P., & CHIEN, J. R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.130 · Cited by 5

Cancer memory as a mechanism to establish malignancy

Lissek, T. (2024) · Biosystems · doi:10.1016/j.biosystems.2024.105381 · Cited by 6

Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma

Redondo-Muñoz, M., Caballé, A., Reisz, J. A., Valero-Leria, A., Olías-Arjona, A., Aldaz, P., D´Alessandro, A., Wellbrock, C., & Arozarena, I. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08578-4 · Cited by 4

Modeling tandem AAG8‐MEK inhibition in melanoma cells

Sun, B., Kawahara, M., & Nagamune, T. (2014) · Cancer Medicine · doi:10.1002/cam4.233 · Cited by 4

Epidermal Growth Factor Receptor and its OncogenicEGFRvIIIVariant in Benign and Malignant Brain Tumors

Kiełbus, M., Rola, R., Jarosz, B., Jeleniewicz, W., Cybulski, M., Stenzel-Bembenek, A., Podkowiński, A., Smok-Kalwat, J., Polberg, K., Trojanowski, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14852 · Cited by 4

EPAC mediates the dual role of cAMP signaling in melanoma

Rodríguez, C. I., & Setaluri, V. (2018) · Oncoscience · doi:10.18632/oncoscience.463 · Cited by 5

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures

Curiel‐Olmo, S., García‐Castaño, A., Vidal, R., Pisonero, H., Varela, I., León‐Castillo, A., Trillo, E. M., González‐Vela, C., García‐Díaz, N., Almaráz, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4545 · Cited by 4

Evidence that the transcriptional repressor ICER is regulated via the N-end rule for ubiquitination

Cirinelli, A., Wheelan, J., Grieg, C., & Molina, C. A. F. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113083 · Cited by 3

NF1-Dependent Transcriptome Regulation in the Melanocyte Lineage and in Melanoma

Larribère, L., & Utikal, J. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153350 · Cited by 3

Melanoma-derived induced pluripotent stem cells

Castro‐Pérez, E., Sadangi, S., Singh, M. K., & Setaluri, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822135-8.00012-4 · Cited by 3

Lineage-Specific Transcription Factors in Carcinogenesis

David, C. J., & Vanharanta, S. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060524-105603 · Cited by 2

Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade

Khan, I. S., Rodriguez-Brotons, A., Bhattacharjee, A., Bezrookove, V., Dar, A. A., de Semir, D., Nosrati, M., Ice, R. J., Soroceanu, L., Leong, S. P. L., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185220 · Cited by 2

Discovery of a first-in-class degrader for microphthalmia-associated transcription factor (MITF)

Shen, W., Yang, H., Chen, Y., Bi, S., Liu, Z., Luo, K., Wang, Z., Wang, J., & Ding, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118367 · Cited by 2

Treatment resistance to melanoma therapeutics on a single cell level

Yao, L., Krasnick, B. A., Bi, Y., Sethuraman, S., Goedegebuure, S. P., Weerasinghe, A., Wetzel, C., Gao, Q., Oyedeji, A., Mudd, J. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72255-9 · Cited by 2

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma

Ballesteros‐Álvarez, J., & Blázquez‐Medela, A. M. (2024) · DNA · doi:10.3390/dna4040025 · Cited by 2

Diverse effects of cAMP signaling in melanoma support the role of distinct cAMP microdomains in melanomagenesis, metastasis, and resistance to therapy

Nardin, C., Fitzpatrick, L. A., & Zippin, J. (2014) · Cited by 2

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells

Datta, K. K., Kore, H., & Gowda, H. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114215 · Cited by 2

Label-Free Melanoma Phenotype Classification Using Artificial Intelligence-Based Morphological ProfilingPreprint

Lattmann, E., Jovic, A., Kim, J. J., Pham, T., Corona, C., Lian, Z., Saini, K., Ray, M., Lu, V., Tastanova, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.28.601235 · Cited by 2

Transcriptome analysis reveals high tumor heterogeneity with respect to re-activation of stemness and proliferation programs

Baranovsky, A., Ivanov, T. M., Granovskaya, M., Papatsenko, D., & Pervouchine, D. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268626 · Cited by 1

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors

Lavallée, E., Roulet-Matton, M., Giang, V., Hurtado, R. C., Chaput, D., & Gravel, S. (2024) · Life Science Alliance · doi:10.26508/lsa.202402912 · Cited by 1

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events

Chen, L., Pruteanu-Malinici, I., Dastur, A., Yin, X., Frederick, D. T., Sadreyev, R. I., & Benes, C. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86694-5 · Cited by 1

An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics

Halford, M. M., He, M. Y., Amin, N., Paquet‐Fifield, S., Achen, M. G., Vincan, E., & Stacker, S. A. (2025) · Growth Factors · doi:10.1080/08977194.2025.2516463 · Cited by 1

Single-cell and spatial transcriptomics identify dihydrolipoic acid succinyltransferase as a promoter of tumor invasion via vascular pathways in cutaneous melanoma

Gu, J., Cheng, X., Xu, J., Cao, H., Liu, P., Wang, Z., Wu, P., Zhang, X. D., Thorne, R. F., Wang, H., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147504 · Cited by 1

PROTAC-based protein degradation: a window of opportunity for melanoma therapy

Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1

Targeting WTAP sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway

Wu, Y., Ju, G., Zhou, X., Wu, J., Zheng, S., & Peng, C. (2026) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500191 · Cited by 1

Predicting condition-aware drug-induced transcriptional responses via a latent diffusion model

Kim, C., & Yoo, S. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag173 · Cited by 1

Mechanistic modeling reveals a configurable AP-1 network governing cell-state heterogeneity and adaptive plasticity in melanoma cells

Degefu, Y. N., Bujnowska, M., Baumann, D. G., & Fallahi‐Sichani, M. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117965 · Cited by 1

The UP s and DOWN s of MITF in melanoma resistance

Kim, H., & Ronai, Z. A. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12338 · Cited by 1

Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine

Scott, K. L., & Powers, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.011 · Cited by 1

[Hypercalcinosis of the hands in scleroderma. 2 case reports].

Eckardt, J., & Towfigh, H. (1994) · PubMed · Cited by 1

An exploitable Achilles heel of MITF?

Silva, C., & Ronai, Z. A. (2022) · Cell Research · doi:10.1038/s41422-022-00762-3 · Cited by 1

Insights into the human cDNA: A descriptive study using library screening in yeast

Alaswad, Z., Attallah, N. E., Aboalazm, B., Elmeslhy, E. S., Mekawy, A. S., Afify, F. A., Mahrous, H. K., Abdalla, A., Rahmoon, M. A., Mohamed, A. A., et al. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2024.100427 · Cited by 1

Role of the orexin system in modulating the tumor microenvironment: implications for tumor progression and cancer therapy

Żuwała, M., Janik, M., & Lewandowski, M. H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152410 · Cited by 1

Cancer as a Paradigm for Translational and Clinical Biomedical Research

Serrano, C., & Demetri, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00032-6 · Cited by 1

METTL3 facilitates hepatic fibrosis progression via m 6 A-YTHDF2 dependent silencing of GPR161Preprint

Pan, X., Bi, Y., Cheng, M., Qian, Z., Wang, L., You, H., Liu, L., Zhang, Z., Meng, X., Huang, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.15.472749 · Cited by 1

ADCY9 (Adenylyl Cyclase 9)

Antoni, F. A. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_140-1 · Cited by 1

Multi‐Drug Resistance in Cancer

Malviya, R., Singh, A. K., & Yadav, D. (2023) · Wiley eBooks · doi:10.1002/9781394209866.ch1 · Cited by 1

FRS2 Is an Oncogene in High Grade Ovarian Cancer

Luo, L. Y. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Screening for melanoma resistance genes in vivo

Dang, M., & Zon, L. I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12368

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors

Benes, C. H. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2014.999504

Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Flaherty, K. T., Wargo, J. A., Root, D. E., & Garraway, L. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.pms-pr10 · Cited by 1

Melanocytic Signaling Promotes Resistance to MAPK Inhibition

(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2013-252

Abstract IA8: BRAF and MEK resistance in melanoma

Herlyn, M., & Villanueva, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.mechres-ia8

Resistance to MAPK inhibition: come see(c) AMP ed up melanoma

Rodríguez, C. I., & Setaluri, V. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12230 · Cited by 1

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66